Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 8, 2003, Pages 335-344

  Shibata, Nobuhito ^a   Kageyama, Michiharu ^a   Kishida, Tomoyuki ^a   Kimura, Keisuke ^a   Yoshikawa, Yukako ^a   Kuwahara, Takeshi ^b   Toh, Jyunichiro ^b   Shirasaka, Takuma ^b   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Ethanol intake; HIV protease inhibitor; Pharmacokinetic interaction; Ritonavir; Saquinavir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; CREATININE; CYTOCHROME P450 3A; LACTATE DEHYDROGENASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIQUID CHROMATOGRAPHY; LIVER DISEASE; MALE; MASS SPECTROMETRY; MONOTHERAPY; NONHUMAN; PATIENT CARE; RAT; TIME; VOMITING;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ALCOHOL DRINKING; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG MONITORING; ETHANOL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, WISTAR; RITONAVIR; SAQUINAVIR;

EID: 0142049740     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.369     Document Type: Article

References (25)

1. Dorsey BD, Levin RB, McDaniel SL, et al. The design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994; 37: 3443-3451.
2. Hoetelmans RMW, Reijers MHE, Weverling GJ, et al. The effect of plasma drug concentrations on HIV clearance rate during quadruple drug therapy. AIDS 1998; 12: F111-F115.
3. Vanhove GF, Gries JM, Verotta D, et al. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997; 41: 2433-2438.
4. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clin Pharmacokinet 1997; 32: 194-209.
5. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-111.
6. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 2784-2791.
7. Shibata N, Matsumura Y, Okamoto H, et al. Pharmacokinetic interaction between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors. J Pharm Pharmacol 2000; 52: 1239-1246.
8. Hayes KA, Brennan B, Chenery R, Houston JB. In vivo disposition of caffeine predicted from hepatocyte data. Drug Metab Dispos 1995; 23: 349-353.
9. Gao W, Kishida T, Kimura K, et al. Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002; 16: 267-273.
10. Yoshikawa Y, Kato K, Sone H, Takada K. Development and evaluation of noncompartmental pharmacokinetic analysis program 'WinHARMONY' using Visual BASIC language having a function of automatic recognition vs time profile. Jpn J Clin Pharmacol Ther 1998; 29: 475-487.
11. Van de Wiel JA, Fijneman PH, Teeuw KB, Van Ommen B, Noordhoek J, Bos RP. Influence of long-term ethanol treatment on rat liver biotransformation enzymes. Alcohol 1993; 10: 397-402.
12. Shor-Posner G, Miguez MJ. Heavy alcohol use hiders HIV therapy: study. Aids Alert 2001; 16: 88-90.
13. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritnavir: a positive drug-drug interaction. Drug Metab Dispos 1999; 27: 902-908.
14. Shibata N, Okamoto H, Kishida T, Gao W, Yoshikawa Y, Takada K. In vitro and in vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. J Pharm Pharmacol 2002; 54: 221-229.
15. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001; 52: 255-264.
16. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interaction. Br J Clin Pharmacol 1998; 46: 101-110.
17. Rogers JD, Zhao J, Liu L, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999; 66: 358-366.
18. Takanaga H, Ohnishi A, Yamada S, et al. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther 2000; 293: 230-236.
19. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163-2175.
20. Durr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604.
21. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77: 517-544.
22. Louis CA, Wood SG, Kostrubsky V, Sinclair PR, Sinclair JF. Synergistic increases in rat hepatic cytochrome P450 s by ethanol and isopentanol. J Pharmacol Exp Ther 1994; 269: 838-845.
23. Rowlands JC, Wang H, Hakkak R, Ronis MJ, Strobel HW, Badger TM. Chronic intragastric infusion of ethanol-containing diets induces CYP3A9 while decreasing CYP3A2 in male rats. J Pharmacol Exp Ther 2000; 295: 747-752.
24. Sweeny DJ, Reinke LA. Effect of ethanol feeding on hepatic microsomal UDP-glucuronyltransferase activity. Biochem Pharmacol 1987; 36: 1381-1383.
25. Vanhaecke T, Lindros KO, Oinonen T, Vercruysse A, Rogiers V. Effect of long-term ethanol exposure on the acinar distribution of hepatic glutathione S-transferase. Drug Metab Dispos 2000; 28: 1470-1474.